Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD

The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.  

Pfeifer_Andrea
Andrea Pfeifer, CEO of AC Immune

The lack of efficacy of the investigational monoclonal antibody, crenezumab, at interim analysis in two Phase III studies, CREAD-1 and CREAD-2, in Alzheimer’s disease came as a shock to the drug’s originator, AC Immune SA. The Jan. 30, 2019 announcement by collaborator, Roche, “was a great disappointment,” says the Swiss biotech’s co-founder and CEO, Andrea Pfeifer.

“I have never seen a pivotal trial better prepared for than this,” said Pfeifer, in an interview with Scrip, in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas